Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Fosun Pharma Acquires Cancer Drug Candidate from US-based Kolltan

publication date: Nov 4, 2016
Fosun Pharma has acquired China rights to an anti-MET monoclonal antibody developed by Kolltan Pharma, a clinical stage New Haven, Connecticut biotech. In preclinical studies, KTN0216 is being tested against neuroblastoma, a form of brain cancer. Kolltan expects KTN0216 will prove to be effective against HGF-dependent and MET-amplified tumors. According to Kolltan's website, KTN0216 is about to begin IND-enabling studies. Financial details of the agreement were not disclosed. More details....

Stock Symbols: (SHA: 600196; HK: 02196)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital